News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

April 28, 2020 Apellis Reports Analysis from Phase 1b Geographic Atrophy Study
April 6, 2020 Paul Fonteyne Joins Apellis Board of Directors
February 27, 2020 Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
February 26, 2020 Apellis Pharmaceuticals to Present at the 40th Annual Cowen Health Care Conference
January 13, 2020 Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
January 8, 2020 Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
January 7, 2020 Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
January 7, 2020 Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
January 2, 2020 Apellis Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
November 26, 2019 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences